MONTREAL, Aug. 28 /PRNewswire/ - BioAxone Therapeutic announced today that all patients enrolled in its Phase I/IIa North American clinical trial of Cethrin® for the treatment of acute spinal cord injury (SCI) have completed their 6 week follow-up visit. All essential information has been collected for the clinical trial report that will be available in the fall. Patients will also have additional follow-ups at 3, 6 and 12 months to monitor the progression of the treatment.
"We are pleased to see that Cethrin®'s profile continues to be safe with no drug related adverse events" said Dr. Frank Bobe, President and CEO of BioAxone.
The Cethrin® clinical trials are being conducted in the following cities: Charlottesville, VA. (1 patient); Cincinnati, OH. (3 patients); Montreal, QC. (7 patients); Philadelphia, PA. (5 patients), Phoenix, AZ. (11 patients); Seattle WA. (1 patient); Toronto, ON. (7 patients); Vancouver, BC. (2 patients).
Cethrin® has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) in December 2005. Cethrin's® active ingredient, BA-210, is a recombinant protein which acts as a Rho GTPase antagonist to promote neuroprotection and neuroregeneration in the central nervous system (CNS). It has been designed by BioAxone to effectively penetrate into CNS tissue, where it has been clearly shown to elicit the rescue and repair of damaged neurons in BioAxone's preclinical research models.
About BioAxone Therapeutic
BioAxone is a privately owned neuroscience company specializing in the development and commercialization of proprietary technologies that target Rho signaling. Established in April 2000 and headquartered in Montreal, Canada, BioAxone has demonstrated expertise in recombinant protein product development and has a focused small molecule program.
Source: BIOAXONE THERAPEUTIC INC.